Having trouble accessing articles? Reset your cache.

Allos falls after earnings, Folotyn data

Allos Therapeutics Inc. (NASDAQ:ALTH) fell $0.87 (15%) to $4.83 on Wednesday after reporting 2Q10 financial results and data from a Phase

Read the full 218 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE